Zenapax (daclizumab) admin to pts with multiple sclerosis (ZAP MS): Effect of intravenously admin humanized monoclonal antibody against the interleukin-2 receptor alpha subunit (daclizumab) on inflammatory activity in the central nervous system.

Trial Profile

Zenapax (daclizumab) admin to pts with multiple sclerosis (ZAP MS): Effect of intravenously admin humanized monoclonal antibody against the interleukin-2 receptor alpha subunit (daclizumab) on inflammatory activity in the central nervous system.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Daclizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Aug 2011 Actual end date changed from Oct 2007 to Aug 2011 as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual patient number (16) added as reported by ClinicalTrials.gov.
    • 09 Sep 2009 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top